Search

Home > Small Caps > Botanix Pharmaceuticals (ASX: BOT) acquires Sofpironium Bromide gel to treat excessive underarm sweating (w/ Vince Ippolito)
Podcast: Small Caps
Episode:

Botanix Pharmaceuticals (ASX: BOT) acquires Sofpironium Bromide gel to treat excessive underarm sweating (w/ Vince Ippolito)
Category: Business
Duration: 00:21:22
Publish Date: 2022-05-04 00:53:00
Description:
Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel. The product has been developed to treat axillary hyperhidrosis, which is a medical condition that results in excessive underarm sweating. Mr Ippolito says the acquisition is a defining deal for Botanix, with Sofpironium Bromide the first and only new chemical entity developed for this condition.
Article:
https://smallcaps.com.au/botanix-acquires-novel-medical-dermatology-asset-treat-axillary-hyperhidrosis/
For more information on Botanix Pharmaceuticals:
https://smallcaps.com.au/stocks/BOT/
Total Play: 0